Announcements Trials
Browse Landscape

Phase

Phase 4 2

Status

Completed 3Unknown 2Terminated 1Recruiting 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 2

Conditions

Carcinoma, Non-Small-Cell Lung 44Colorectal Neoplasms 22Breast Neoplasms 22Stomach Neoplasms 21Neoplasms 18Esophageal Squamous Cell Carcinoma 12Neoplasm Metastasis 11Nasopharyngeal Carcinoma 11Lung Neoplasms 11Rectal Neoplasms 9Colonic Neoplasms 8Pancreatic Neoplasms 7Uterine Cervical Neoplasms 6Esophageal Neoplasms 6Squamous Cell Carcinoma of Head and Neck 5Ovarian Neoplasms 5Osteosarcoma 5Brain Neoplasms 5Small Cell Lung Carcinoma 4Recurrence 4Glioblastoma 4Gastrointestinal Neoplasms 4Precision Cell Immunotherapy 3Melanoma 3Lymphoma, Non-Hodgkin 3Lymphoma 3Head and Neck Neoplasms 3Gastrointestinal Diseases 3Digestive System Neoplasms 3Carcinoma, Ovarian Epithelial 3

Interventions

Docetaxel 5Pemetrexed 4Capecitabine 4pembrolizumab 3Oxaliplatin 3icotinib 2Radiation 2Paclitaxel 2Gemcitabine 2Gefitinib 2Fluorouracil 2Drug Therapy 2Chemoradiotherapy 2Carboplatin 2sintilimab 1rucaparib 1regorafenib 1olaparib 1lenvatinib 1iron isomaltoside 1000 1ipatasertib 1iopromide 1gluconic acid 1elemene 1capecitabine-irinotecan combination 1aumolertinib 1atezolizumab 1anlotinib 1aflutinib 1XELOX 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Adenocarcinoma × Drug Therapy × Clear all
NCT01665417 2017-02-08

Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma

Betta Pharmaceuticals Co., Ltd.

Phase 4 Unknown
100 enrolled
Tumor-Agnostic

Adenocarcinoma

NCT02103257 2015-04-29

Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma

Betta Pharmaceuticals Co., Ltd.

Phase 4 Unknown
192 enrolled
Tumor-Agnostic

Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡